CSBio CSBio

X
[{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","amount":"$380.0 million","upfrontCash":"$10.0 million","newsHeadline":"Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Heptares"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Biohaven will get exclusive global rights to develop, manufacture and commercialize a portfolio of novel, small-molecule CGRP receptor antagonists discovered by Sosei Heptares for the treatment of CGRP-mediated disorders. The portfolio includes the lead candidate HTL0022562.

            Lead Product(s): HTL0022562

            Therapeutic Area: Neurology Product Name: HTL0022562

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Biohaven Pharmaceuticals

            Deal Size: $380.0 million Upfront Cash: $10.0 million

            Deal Type: Collaboration December 01, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY